- Home
- ACU vs PROK Comparison
ACU vs PROK Comparison
Compare ACU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACU
- PROK
- Stock Information
- Founded
- ACU 1867
- PROK 2015
- Country
- ACU United States
- PROK United States
- Employees
- ACU N/A
- PROK N/A
- Industry
- ACU Industrial Machinery/Components
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACU Consumer Discretionary
- PROK Health Care
- Exchange
- ACU Nasdaq
- PROK Nasdaq
- Market Cap
- ACU 145.9M
- PROK 129.5M
- IPO Year
- ACU N/A
- PROK N/A
- Fundamental
- Price
- ACU $39.20
- PROK $0.77
- Analyst Decision
- ACU
- PROK Buy
- Analyst Count
- ACU 0
- PROK 3
- Target Price
- ACU N/A
- PROK $4.50
- AVG Volume (30 Days)
- ACU 14.0K
- PROK 902.6K
- Earning Date
- ACU 07-18-2025
- PROK 08-08-2025
- Dividend Yield
- ACU 1.50%
- PROK N/A
- EPS Growth
- ACU N/A
- PROK N/A
- EPS
- ACU 2.48
- PROK N/A
- Revenue
- ACU $195,491,991.00
- PROK $306,000.00
- Revenue This Year
- ACU $4.87
- PROK $54.34
- Revenue Next Year
- ACU $3.65
- PROK N/A
- P/E Ratio
- ACU $16.11
- PROK N/A
- Revenue Growth
- ACU 2.56
- PROK N/A
- 52 Week Low
- ACU $32.85
- PROK $0.46
- 52 Week High
- ACU $50.00
- PROK $2.59
- Technical
- Relative Strength Index (RSI)
- ACU 51.35
- PROK 48.64
- Support Level
- ACU $37.13
- PROK $0.61
- Resistance Level
- ACU $39.93
- PROK $1.02
- Average True Range (ATR)
- ACU 1.00
- PROK 0.13
- MACD
- ACU 0.08
- PROK -0.02
- Stochastic Oscillator
- ACU 61.42
- PROK 37.16
About ACU Acme United Corporation.
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.